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Background: The purpose of this study was to develop a method for targeted delivery of 
10-hydroxycamptothecin (HCPT)-loaded nanoparticles (NPs) to cancer cells.
Methods: We first used a supercritical antisolvent process to prepare micronized HCPT 
(nHCPT), and then folate-conjugated human serum albumin (HSA) nHCPT-loaded NPs 
(FA-HSA-nHCPT-NPs) were prepared using a NP-coated method combined with a desolvation 
technique. The amount of folate conjugation was 16 µg · mg−1 HSA.
Results: The particle size of the spherical nHCPT microparticles obtained was 118.5 ± 6.6 nm. 
The particle size and zeta potential of the FA-HSA-nHCPT-NPs were 233.9 ± 1.2 nm 
and −25.23 ± 2.98 mV, respectively. The FA-HSA-nHCPT-NPs exhibited a smooth surface and 
a distinct spherical shape, and the results of differential scanning calorimetry and X-ray diffrac-
tion indicated that the FA-HSA-nHCPT-NPs presented in a nanostructured amorphous state. 
The FA-HSA-nHCPT-NPs showed sustained-release characteristics for 120 hours in vitro, with 
a drug-loading content of 7.3% and an encapsulating efficiency of 79.1%.
Conclusion: The FA-NPs were effective delivery systems for uptake by SGC7901 cells com-
pared with folate-free NPs. These results suggest that a NP-coated method combined with a 
desolvation technique is effective for preparing NPs with drugs having poor solubility in water 
and most organic solvents, using albumin as the wall material. FA-HSA-NPs are a stable delivery 
system and have the potential for targeted delivery of anticancer drugs.
Keywords: nanoparticle-coated, desolvation technique, 10-hydroxycamptothecin, human serum 
albumin, folate, targeted delivery
Introduction
Camptothecin and related analogs have shown promise as anticancer agents, which could 
lead to the death of tumor cells by targeting the nuclear enzyme, topoisomerase I, and 
inhibiting the relegation of the cleaved DNA strand.1 One of the camptothecin analogs, 
hydroxycamptothecin (HCPT), a plant alkaloid derived from Camptotheca acuminata, 
has demonstrated strong antitumor activity against gastric, lung,   ovarian, breast, and 
pancreatic carcinomas.2 Unfortunately, HCPT has poor solubility in water and other 
physiologically acceptable solvents, which limits its clinical   application. The earlier 
clinical trials used its highly water-soluble sodium salt, but the opening of the active 
lactone ring at physiological pH limited the tumor response, was much less active, and 
was highly toxic.3–5 To overcome these limitations, many attempts had been made to 
develop high-performance delivery systems. Niosomes,6 micelles,7,8 and nanoparticles9 International Journal of Nanomedicine 2011:6
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Figure 1 schematic process for preparation of micronized 10-hydroxycamptothecin-
loaded folate-conjugated human serum albumin nanoparticles.
Abbreviations: nhPcT, micronized 10-hydroxycamptothecin; FA-hsA-nhcPT-
NPs, micronized 10-hydroxycamptothecin-loaded folate-conjugated human serum 
albumin nanoparticles.
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had been explored with some success. Among these delivery 
systems, albumin has been used widely in recent years because 
of its biodegradability,   stability, and lower toxicity, which 
significantly retard the lactone ring opening.10,11
Many targeting agents have been coupled with drug 
delivery systems to improve their site-specific targeting. 
Folic acid is a low- molecular- weight (441 Da) vitamin, the 
receptor for which is frequently overexpressed in human 
cancer cells, but is restricted in most normal tissues.12,13 Folate 
conjugates of radiopharmaceutical agents, chemotherapeutic 
agents, antisense oligodeoxynucleotides, immunotherapeutic 
agents, and plasmids had all been delivered to cancer cells 
overexpressing the folate receptor.14
The supercritical antisolvent process (SAS) is a new 
micronization technology developed in recent years, which 
has been adapted for preparation of drug nanocrystals 
because of its inertia and low temperature.15 In this study, we 
prepared micronized hydroxycamptothecin (nHCPT) using 
SAS, and folate-conjugated (FA) human serum albumin 
(HSA) nanoparticles (NPs) were considered to be promising 
carriers. FA-HSA-nHCPT-NPs were prepared by a NP-coated 
method combined with a desolvation technique. The prepa-
ration and related characteristics of the NPs obtained were 
investigated, and an in vitro release test and measurement of 
uptake of NPs by cancer cells were also conducted.
Materials and methods
Materials
10-HCPT (98%) and HSA were provided by Hisun Phar-
maceutical Co Ltd (Zhejiang, China). Folate-free RPMI 
1640, folic acid, fluorescein isothiocyanate (FITC), and 
phosphate-buffered solution (pH = 7.4) were purchased from 
Sigma-Aldrich (St. Louis, MO). RPMI 1640 and trypsin-
ethylenediaminetetraacetic acid were purchased from Gibco 
(Invitrogen, Carlsbad, CA). Acetonitrile was of high-pressure 
liquid chromatography grade and all the other reagents were 
of analytical grade.
Preparation of nhcPT by sAs
nHCPT was prepared by SAS, based on the method used in 
the early research.15 Three important parameters in the SAS 
process, ie, the pressure of the precipitation chamber, the 
concentration of HCPT in dimethyl sulfoxide solution, and 
the speed of the liquid pump, were 25 mPa, 6 mg⋅mL−1, and 
13.3 mL⋅min−1, respectively.
Preparation of FA-hsA
The method used for preparing an N-hydroxysuccinimide ester 
of folate (NHS folate) had been reported.16 The   carboxylic 
groups of the NHS folate were conjugated with the amino 
groups of the HSA under alkaline conditions. NHS folate 
2.5 mg was dissolved in 1 mL carbonate/  bicarbonate   buffer 
(0.1 M, pH = 10), and added slowly to the stirring HSA 
solution, and the reaction was maintained for 45   minutes 
at ambient temperature. The unreacted NHS folate was 
precipitated by adjusting the pH to the 4–5 range using 
0.1 M HCl. The mixture was treated in an ultrasonicator for 
20 minutes, and centrifuged at 12,000 rpm for 10 minutes 
three times. The supernatant, FA-HSA, was lyophilized to 
give a yellow powder.
Preparation of FA-hsA-nhcPT-NPs
FA-HSA-nHCPT-NPs were prepared using a NP-coated 
method combined with a desolvation technique. nHCPT 
2 mg was added to 3.0 mL of purified water, and sonicated 
until the nHCPT was completely dispersed. The nHCPT 
suspension was added slowly to the stirring 3.0 mL FA-HSA 
purified water solution (6.7 mg⋅mL−1), and the pH of the 
  mixture was adjusted to 6.0 to protect the potent lactone 
form of HCPT. Ethanol 6.6 mL was added dropwise under 
constant stirring, and 0.2 mL of 0.25% glutaraldehyde 
  solution was added to the reaction mixture as a cross-
linking agent. The mixture was continuously stirred for 
18 hours to obtain the NPs   (Figure 1). The mixture was 
then centrifuged at 40,000 rpm for 10   minutes to separate 
the unloaded nHCPT, and was washed with purified water 
twice. The supernatant was   collected to detect the drug-
loading and encapsulating   efficiency, the precipitation 
was redispersed with purified water, 1 mL was withdrawn 
for particle size measurement and zeta potential analysis, International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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and the rest was lyophilized. Mannitol was added as a 
lyoprotectant if needed. The control FA-HSA-NPs were 
prepared according to the   aforementioned process, but did 
not contain nHCPT.
Determination of amount of FA-hsA
The lyophilized FA-HSA-NPs were redispersed with purified 
water and digested by trypsin (0.1 mg⋅mg−1 HSA) overnight 
at room temperature, then the resulting tryptic hydrolysis of 
FA-HSA-NPs was detected using an ultraviolet spectropho-
tometer (Shimadzu, Tokyo, Japan) in the 270–450 nm range. 
The degree of folate conjugated with HSA was calculated 
relative to a NHS folate reference of y = 0.016x + 0.002, 
R2 = 0.9999 (y, NHS folate concentration in µg⋅mL−1; 
x, absorption).
characterization of FA-hsA-nhcPT-NPs
The mean particle size and zeta potential of the FA-HSA-
nHCPT-NPs were determined by laser light scattering and a 
zeta potential analyzer (Zetaplus, Brookhaven Instruments, 
  Holtsville, NY), respectively. The MSD analysis method 
was used to obtain laser light scattering measurements. 
The   samples were diluted with purified water and mea-
sured according to the average number of particles at room 
temperature. Each experiment was determined in triplicate. 
The morphology of the nanoparticles was observed by 
scanning electron   microscopy (FEI Co, Eindhoven, The 
Netherlands).
The X-ray diffraction patterns were collected in trans-
mission using an X-ray diffractometer with a rotating anode 
(Philips, Xpert-Pro, The Netherlands). The scanning rate 
was 5°C⋅min−1, and the diffraction angle (2θ) was recorded 
at 5–80°C. Cu Kα1 radiation was generated at 30 mA and 
50 kV as the X-ray source.
Differential scanning calorimetry analysis was performed 
using a TA-60WS Thermal Analyzer (Shimadzu, Japan). 
The curves of the samples were recorded at a heating rate 
of 10°C⋅min−1 from 40°C to 300°C.
Drug-loading and encapsulating efficiency
To evaluate drug-loading and encapsulating efficiency, the 
unloaded nHCPT in the supernatant after centrifugation was 
determined by reversed-phase high-pressure liquid chroma-
tography. A high-pressure liquid chromatography system 
equipped with a Jasco 975 ultraviolet detector and HIQ 
SIL C18 column (250 mm × 4.6 mm, 5 µm; Jasco,Tokyo, 
Japan) was used. The mobile phase comprised 35% (v/v) 
acetonitrile in water (pH = 5.5) at 1 mL⋅min−1. Detection 
was performed at 370 nm. All samples were conducted in 
triplicate.   Drug-loading and encapsulating efficiency were 
determined by equations (1) and (2).
Loading  HCPT HCPT
Nanoparticles
(total)( in the supernatant) =
−
( (total)
   100%
content (%)
×
  (1)
Encapsulating  HCPT HCPT
HCPT
(total)( in the supernatant)
(to
=
−
t tal)
 100%
efficiency (%)
×
  (2)
In vitro release of nhcPT  
from FA-hsA-nhcPT-NPs
Release of nHCPT from the nanoparticles was carried out in 
phosphate-buffered solution (pH = 7.4) as follows. FA-HSA-
nHCPT-NPs were dispersed in 1 mL phosphate-buffered 
solution, and placed in a dialysis bag (molecular weight 
cutoff 3500 Da). The end-sealed dialysis bag was incubated 
in 100 mL phosphate-buffered solution at 37°C with gentle 
agitation. At predetermined time intervals, 10 mL of dialysis 
solution was withdrawn and replaced with an equal volume 
of fresh phosphate-buffered solution. The concentration of 
HCPT was determined by high-pressure liquid chromatog-
raphy as described earlier. Each sample was determined in 
triplicate.
cell culture
SGC7901 and A549 cells were used in the NP cell uptake 
studies, and were purchased from the Shanghai Cell Line 
Bank (Chinese Academy of Sciences, Shanghai, China). 
The cells were cultured in RPMI 1640 supplemented with 
10% heat-inactivated fetal bovine serum, 100 U⋅mL−1 
penicillin, and 100 µg⋅mL−1 streptomycin in a humidified 
atmosphere containing 5% CO2 at 37°C. In the cell uptake 
studies, folate-free RPMI 1640 supplemented with 5% 
heat-inactivated fetal calf serum was used to minimize the 
effect of folate.17
cell uptake
The FA-HSA-NPs and HSA-NPs were labeled with 
FITC to observe the extent of uptake by SGC7901 and 
A549 cells. The cells were seeded at 3 × 105 cells per well 
and cultured in 12-well plates for one day. Each well was 
incubated with FITC-labeled FA-HSA-NPs or HSA-NPs 
at indicated concentrations for four hours at 37°C. The 
cells were washed three times with phosphate-buffered 
solution, and observed by laser scanning confocal micros-
copy (Nikon, Tokyo, Japan). The excitation wavelength 
was 488 nm.International Journal of Nanomedicine 2011:6
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Figure 2 A) Determination of folate content conjugated with human serum albumin, a) N-hydroxysuccinimide ester of folate, b) tryptic hydrolysis of folate-conjugated 
human serum albumin nanoparticles, c) tryptic hydrolysis of human serum albumin nanoparticles; the particle size distribution of B) micronized 10-hydroxycamptothecin, 
C) micronized 10-hydroxycamptothecin-loaded folate-conjugated human serum albumin nanoparticles, D) hsA-nhcPT-NPs; the morphology observation of E) raw 
hydroxycamptothecin, F) micronized hydroxycamptothecin, G) micronized 10-hydroxycamptothecin-loaded folate-conjugated human serum albumin nanoparticles, and 
H) human serum albumin-loaded 10-hydroxycamptothecin nanoparticles, by scanning electron microscopy.
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Results and discussion
characterization of FA-hsA-nhcPT-NPs
In this research, FA-HSA-nHCPT-NPs were prepared 
based on SAS micronized 10-HCPT using a NP-coated 
method combined with desolvation technology. The 
method included two steps. As showed in Figure 1, the 
first step was the desolvation process. We used ethanol 
as the   desolvating agent to decrease the solubility of the 
coating material (FA-HSA) gradually in water, and 0.25% 
  glutaraldehyde solution was added to crosslink the desol-
vated   FA-HSA. The second step was the NP-coated process, 
whereby the nHCPT was loaded through electrostatic inter-
action between the drug and FA-HSA. As the core, nHCPT 
was coated gradually under stirring for the indicated time 
interval, and   FA-HSA-nHCPT-NPs were formed.
The amount of folate conjugated with HSA was deter-
mined using an ultraviolet spectrophotometer. As show in 
Figure 2A, the absorption peaks of tryptic hydrolysis for the 
FA-HSA-NPs at 280 nm and 365 nm were consistent with 
the absorption peak of NHS folate, which confirmed that the 
folate was successfully conjugated with HSA. The amount 
of folate associated with HSA was 16 µg⋅mg−1, which was 
evaluated according to the standard curve of NHS folate. 
Folate could enable binding, promote cell uptake, and thus 
increase toxicity when 2–3 folate groups were inserted per 
HSA molecule.18 Our findings were as follows.
Mean diameter and size distribution of the prepared NPs 
were determined by laser light scattering. nHCPT had an 
average diameter of 118.5 ± 6.6 nm (Figure 2B), the mean 
diameters of FA-HSA-nHCPT-NPs and HSA-nHCPT-NPs 
were 233.9 ± 1.2 nm and 192.5 ± 7.4 nm, respectively. 
HSA-nHCPT-NPs were of smaller size compared with 
  FA-HSA-nHCPT-NPs, both of which had a narrow size 
distribution (Figures 2C and 2D). The mean diameters of 
control FA-HSA and HSA nanoparticles (unloaded nHCPT) 
were 159.0 ± 3.3 nm and 140.1 ± 2.6 nm, respectively.
The surface charge has a significant effect on the stabil-
ity of a colloidal nanoparticle system in medium.19 The zeta 
potential of FA-HSA-nHCPT-NPs and HSA-nHCPT-NPs 
were −25.23 ± 2.98 mV and −25.40 ± 2.55 mV, respectively, 
which indicates stability.
The morphology of the NPs was investigated by scanning 
electron microscopy. In Figure 2E, the unprocessed HCPT 
particles were in irregular bulk form or seen as lamelliform 
crystals, with diameters in the 1–30 µm range. In contrast, as 
shown in Figure 2F, processed HCPT were seen as spherical 
microparticles and were of uniform distribution, with no drug 
crystals visible. FA-HSA-nHCPT-NPs and HSA-nHCPT-
NPs exhibited a smooth surface and a distinct spherical shape 
without conglutination (Figures 2G and 2H).
The X-ray diffraction results for raw HCPT, nHCPT, and 
FA-HSA-nHCPT-NPs are shown in Figure 3A. The peaks International Journal of Nanomedicine 2011:6
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of raw HCPT at 2θ = 9.9°, 18.7°, 20.1°, and 27.6° show the 
crystalline structure of raw HCPT. Nevertheless, nHCPT only 
presented a weak peak at 2θ = 9.9°, indicating that most of 
the processed HCPT might be present in an amorphous state. 
The characteristic peaks of HCPT disappeared in the pattern 
of FA-HSA-nHCPT-NPs. The results show that nHCPT had 
been coated as the central core by the hydrophilic outer shell 
of FA-HSA.
Figure 3B shows the results of differential scanning 
calorimetry. The raw HCPT exhibited an obvious melting 
process, with a peak of 279.8°C, which implied the crystalline 
form of HCPT. No melting process was observed for nHCPT 
and FA-HSA-nHCPT-NPs, indicating that both were nano-
structured and noncrystalline. The results were consistent 
with the results of the X-ray diffraction analysis.
In vitro release of nhcPT from NPs
FA-HSA-nHCPT-NPs used in the in vitro release study had 
a drug-loading content of 7.3% and a high encapsulating 
efficiency of 79.1%. Figure 4 shows the release profiles of 
nHCPT and FA-HSA-nHCPT-NPs in vitro over 120 hours. 
nHCPT was released very slowly from the FA-HSA-nHCPT-
NPs. Less than 25% of the loaded nHCPT was released from 
the FA-HSA-nHCPT-NPs after 16 hours, and the release 
profile exhibited a very steady sustained-release pattern, 
with a negligible initial burst release. However, nHCPT had 
fast release properties. Over 90% of the nHCPT had been 
released within 16 hours. The release characteristics of the 
FA-HSA-nHCPT-NPs were in accordance with the Higuchi 
kinetics model, with an equation of y = −111.627e(−x/67.70) + 
113.228 (R2 = 0.996).
These data suggest that FA-HSA-nHCPT-NPs have 
a significant effect on sustained release. Being the main 
  constituent of the hydrophilic outer part, HSA could increase 
the solubility and absorption rate of the insoluble drug. 
Combining drugs with albumin could prevent release at the 
injection site and enable the drug to be released slowly.20,21
Uptake of FITc-labeled  
NPs by tumor cells
FITC-labeled albumin nanoparticles with or without folic 
acid ligand was used in a previously reported uptake study.22 
Tumor cells were treated with different concentrations of 
FITC-labeled nanoparticles for four hours. A significant 
amount of FA-HSA-NPs was attached to the surfaces of 
SGC7901 cells, and numerous green fluorescent spots were 
observed around the SGC7901 cell surface (Figure 5E). The 
intensity of fluorescence around the cells was enhanced in 
a concentration-dependent pattern as shown in Figure 5F. 
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However, the intensity of fluorescence around the SGC7901 
cell surface was very weak when the cells were incubated 
with HSA-NPs which lacked folic acid ligand (Figures 5B 
and 5C). When folate receptor-deficient A549 cells were 
incubated with FITC-labeled FA-HSA-NPs and HSA-NPs 
(0.5 mg⋅mL−1), there were no obvious fluorescence spots 
on the cell surfaces because of the lack of folate receptors 
(Figures 5A and 5D). This implied that SGC7901 cells were 
more sensitive to FA-HSA-NPs, and higher internalization 
of FA-HSA-NPs could be observed in comparison with 
HSA-NPs, which is consistent with the report by Han et al.23 
FA-HSA-NPs were effective delivery systems for uptake by 
tumor cells.
The search for effective drug target delivery systems is 
a hot topic in tumor therapy. NPs represent promising drug 
carriers, especially for specific transport of anticancer 
drugs to the tumor site, because of less drug leakage, high 
  drug-loading efficiency, good storage stability, and an 
  ability to circumvent multidrug resistance in cancer cells.24 
NPs made of HSA have several specific advantages, such 
as being well tolerated without any serious side effects, and 
are biodegradable. Importantly, HSA offers the benefits of 
being able to carry functional groups (ie, amino and carboxy-
lic groups) that could be used for surface modifications.25 
Therefore, folate as a drug targeting ligand has often been 
used in the recent years for cancer-targeted drug delivery 
because of its high affinity (10−10 M)26 through association 
with albumin.
Generally, there were two different methods applied for 
albumin NP preparation, ie, desolvation technology and 
emulsion formation. The desolvation of albumin with organic 
solvents followed by crosslinking with glutaraldehyde is 
commonly used to assemble protein NPs.27 The classical 
desolvation process is illustrated in Figure 6. Drugs were dis-
solved in water together with albumin or added to an albumin International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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solution, and the desolvation agent was subsequently added 
dropwise into the mixture solution under stirring. When 
adding the desolvation agent to the protein solution, the 
albumin was phase-separated as its water solubility dimin-
ished, and nanoparticles were then formed from the albumin 
solution. Simultaneously, the drug molecules in the solution 
were encapsulated or diffused into the NPs.28–30 In our early 
research, we dissolved drug in the desolvation agent which 
was subsequently added to the BSA solution and crosslinked 
with glutaraldehyde to prepare NPs. The NPs obtained were 
then decorated with folic acid under alkaline conditions. 
Unfortunately, the lactone form of HCPT was insoluble in 
both water and conventional desolvating agents, eg, ethanol 
and acetone. Moreover, most HCPT molecules existed in 
the inactive carboxylated form at physiological pH values. 
Therefore, traditional desolvation technology was not   suitable 
for the preparation of FA-HSA-nHCPT-NPs.
In the early research, 10-HCPT-loaded bovine serum 
albumin NPs were prepared by Yang et al31 using a refor-
mative emulsion-heat stabilization technique. HCPT and 
bovine serum albumin were dissolved together in NaOH 
solution, and added to castor oil containing 2% Span-80 
to form a water/oil emulsion. After stirring and high-speed 
emulsification, HCPT-loaded NPs were formed. During the 
process, HCPT transformed from lactone to carboxylate and 
finally back to the lactone form. Although the investigators 
obtained HCPT-loaded bovine serum albumin NPs success-
fully, much more castor oil was used (aqueous to nonaqueous 
phase ratio 1:5), which could induce unpredictable toxicity. 
Removal of organic residues was needed. The NPs obtained 
had a particle size of about 600 nm. According to Müller,32 
albumin particles below 500 nm were difficult to obtain by 
the emulsion method. Moreover, perhaps because of the 
transformation between the lactone and carboxylate forms in 
the preparation process, these NPs had a lower drug-loading 
content and encapsulating efficiency (2.21% and 57.5%, 
respectively).
In our study, we first conjugated folate with HSA, 
and used a NP-coated method combined with a desolva-
tion technique to prepare FA-HSA-nHCPT-NPs without 
changing the lactone of HCPT into the carboxylate form. 
The preparation process is described earlier. The pH of the 
reaction system was adjusted to 6.0; on the one hand, it was 
used to protect the potent lactone form of nHCPT and, on 
the other hand, according to the drug-loading mechanism 
reported by Huang et al.33 The lactone form of nHCPT was 
loaded by electrostatic interaction between the negative 
charges of the FA-HSA and the positive charges of the drug 
when the pH of the solution was adjusted to higher than the 
isoelectric point of HSA. NPs obtained by this method had 
a smaller average diameter (less than 240 nm), and higher 
drug-loading content and encapsulating efficiency (7.3% 
and 79.1%, respectively). Used as the desolvation agent, 
ethanol was removed, followed by centrifugation and, finally, 
  lyophilization. Many different NP-coated methods have been 
used to prepare microparticles, emulsions, and magnetic NPs, 
and special construction could modify drug release from the 
particles.34–36
The mechanism of drug release from albumin NPs has 
been shown to be dependent on the location of the drug in 
the carrier, as well as on the properties of the NP matrix.37 
There were two main forms of drug associated with albu-
min NPs; one is adsorption onto the particle surface and the 
other is inclusion in the NP matrix. If the albumin matrix is 
stable enough, the release of HCPT from NPs appears to be 
difficult.31 The crosslinking process (ie, time of crosslinking 
and glutaraldehyde concentration) plays an important role in 
the stability and drug release from albumin NPs.38,39 In the 
process of FA-HSA-nHCPT-NP preparation, we used 0.25% 
glutaraldehyde as a crosslinking agent, which   provided 
sustained-release of NPs for more than 120 hours.
In comparison with folate-free HSA nanoparticles, the 
FA-HSA-NPs showed higher uptake by SGC7901 cells which 
were sensitive to folic acid ligand. This suggests that if cancer 
cells only overexpressed folate receptors on their surface, 
FA-HSA-NPs could have a better uptake effect. FA-HSA-NPs 
show multivalent interactions with folate receptors, which 
generally exist in large clusters.40 Therefore, a FA-HSA-NP 
might occupy many receptors because of its special structure, 
and in this way may have high affinity for tumor cells.
Conclusion
We used SAS technology to prepare nHCPT, and our results 
indicate that nHCPT has a smaller diameter and narrow 
size distribution compared with raw HCPT. Moreover, 
nHCPT presented in an amorphous state. We prepared 
FA-HSA-nHCPT-NPs using a NP-coated method combined 
with a desolvation technique. The method used was advanced 
and simple. The spherically shaped HCPT-loaded NPs 
obtained had a small average diameter, and their drug-loading 
content and encapsulating efficiency were considerable. The 
sustained-release characteristics of the   FA-HSA-nHCPT-NPs 
indicated that HCPT was well protected in a   physiological 
environment (pH = 7.4). There was marked uptake of 
FA-HSA-nHCPT-NPs by cancer cells in vitro. FA-NPs con-
stitute a promising drug delivery system, and we will focus International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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our research energy on their antitumor effects. Their body 
distribution and tumor-targeting potential in vivo should also 
be evaluated in further research.
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